Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Research analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Puma Biotechnology in a note issued to investors on Thursday, October 17th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.72 per share for the year, up from their previous forecast of $0.69. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.25 per share.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to analyst estimates of $43.99 million. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. During the same quarter in the prior year, the company posted $0.05 earnings per share.
A number of other research firms also recently commented on PBYI. StockNews.com downgraded Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, August 2nd.
View Our Latest Stock Analysis on PBYI
Puma Biotechnology Price Performance
Shares of NASDAQ PBYI traded down $0.07 during mid-day trading on Monday, reaching $2.81. The company's stock had a trading volume of 120,066 shares, compared to its average volume of 461,586. The firm has a market capitalization of $135.55 million, a PE ratio of 8.73 and a beta of 1.09. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.32 and a quick ratio of 1.23. The stock has a fifty day moving average of $2.62 and a two-hundred day moving average of $3.56. Puma Biotechnology has a 52 week low of $2.13 and a 52 week high of $7.73.
Institutional Investors Weigh In On Puma Biotechnology
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in Puma Biotechnology during the third quarter valued at approximately $34,000. Frazier Life Sciences Management L.P. raised its holdings in shares of Puma Biotechnology by 8.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company's stock worth $9,984,000 after buying an additional 246,264 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Puma Biotechnology in the second quarter worth approximately $58,000. Affinity Asset Advisors LLC purchased a new stake in shares of Puma Biotechnology in the second quarter worth approximately $815,000. Finally, Squarepoint Ops LLC raised its holdings in shares of Puma Biotechnology by 17.7% in the second quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company's stock worth $233,000 after buying an additional 10,757 shares during the period. 61.29% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Puma Biotechnology news, Director Michael Patrick Miller sold 23,358 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $3.49, for a total transaction of $81,519.42. Following the sale, the director now directly owns 47,000 shares in the company, valued at $164,030. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 23.70% of the stock is owned by company insiders.
About Puma Biotechnology
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Featured Articles
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
